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Summary. Rat neural lobes and isolated nerve terminals 
from the neurohypophysis were stimulated in the 
presence of different opioid agonists and antagonists. 
The secretion of arginine vasopressin and oxytocin and 
rise in cytoplasmic calcium induced by depolarization 
were analyzed by radioimmunoassay and the fluorescent 
probe fura-2, respectively. The kappa-agonists dynor- 
phin A~t- t3) and dynorphin A~_ ~) did not affect electri- 
cally evoked release of vasopressin, although oxytocin 
release was slightly reduced. U-50 488, a relatively spe- 
cific kappa-receptor agonist, had no effect on the amount 
of vasopressin or oxytocin secreted, although it signifi- 
cantly reduced K +-evoked changes in [Ca 2 +]i in isolated 
nerve endings. Two kappa-receptor antagonists, MR 
2266 and diprenorphin, alone had no effect on vasopres- 
sin and oxytocin secretion from isolated nerve endings 
depolarized with potassium. Opioid agonists less selec- 
tive for the kappa receptors, etorphin and ethylketocy- 
clazocin, were found to inhibit the release of both vaso- 
pressin and oxytocin significantly. Naloxone, a non- 
selective opiate receptor antagonist, alone had no effect 
on vasopressin release but potentiated the electrically 
evoked release of oxytocin. Naloxone also could over- 
come the inhibitory effect of etorphin on oxytocin and 
vasopressin release observed after electrical stimulation 
of the neural lobe. A number of inconsistencies therefore 
exist between the effects of opioid agonists and antago- 
nists on neuropeptide release and on the evoked changes 
in [Ca 2 +]i. In view of these inconsistencies and the high 
concentrations of opioid agonists and antagonists 
necessary to modify release, we conclude that it is doubt- 
ful that opioid molecules have a p h y s i o l o g i c a l  role in 
controlling neurohypophysial secretion. 
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Introduction 
The role of opiates in the release of neurohormones fro1T1 
the hypothalamo-neurohypophysial system has been ex- 
tensively studied over the last decade. However, the pub- 
lished data are contradictory. For example, Iversen et al. 
(1980) have reported that Leu-enkephalin inhibits the 
release of vasopressin (AVP) from the neural lobe. Al- 
though this has been confirmed (Lightman et al. 1982; 
A1-Zein et al. 1984), other studies have failed to re- 
produce these results (Denker et al. 1982; Nordmann et 
al. 1986). In addition, the effects of the 8-agonist Leu- 
enkephalin are puzzling, as it has been shown recently 
that the neural lobe contains predominantly opioid kap- 
pa receptors (Pesce et al. 1987). Studies on the effects of 
naloxone, which binds preferentially (but not only) to 
opioid g-receptors, have also resulted in contradictory 
reports. Whereas some investigations have shown no 
effect on electrically induced release of vasopressin (Bick- 
nell and Leng 1982; Nordmann et al. 1986) or oxytocin 
(OT) (Pitzel and Konig 1984), other reports have in- 
dicated that naloxone either greatly potentiates OT re- 
lease (Bicknell and Leng 1982), and to a lesser extent that 
of AVP (Zhao et al. 1988a), or that it decreases evoked 
AVP secretion (Knepel and Meyer 1983). Furthermore, 
DAGO, a g-receptor agonist, was found to partially 
inhibit both AVP and OT release (Zhao et al. 1988a). 
Most recently, it has been shown that the kappa-type 
opioid receptors are found not only on pituicytes, as first 
reported (Lightman et al. 1983), but also on the neurose- 
cretory nerve endings (Gerstberger and Barden 1986; 
Pesce et al. 1987; Falke and Martin 1988). Moreover, 
kappa-receptor agonists have been shown to inhibit the 
release of AVP and OT from electrically stimulated neu- 
ral lobes (Zhao et al. 1988a) and from potassium- 
depolarized nerve endings (Zhao et al. 1988b). In the 
present study, we have continued our previous investiga- 
tions (Nordmann et al. 1986) on the role of opioid mole- 
cules in regulating exocytosis in the rat neural lobe. The 
experiments have been performed on both intact neuro- 
hypophyses and on preparations of isolated nerve end- 
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ings. Here, we report the effects on the release of AVP 
and OT, together with changes in cytoplasmic-free cal- 
cium concentration ([Ca2+]~) to application of various 
opioid agonists and antagonists. 
Material and methods 
Perfusion of neural lobes and isolated neurosecretory 
nerve endings 
Neurohypophyses were isolated from male rats (Wistar 
or Sprague Dawley) weighing 220-240 g and were 
separated from the pars intermedia. Single neural lobes 
were impaled on one of a pair of platinum electrodes, 
which were positioned into a perfusion chamber. The 
chamber, 30-50 gl in volume, was maintained at 37~ 
and perfused during the first 45 min of incubation at a 
rate of 25 gl/min, which was then increased to 50 gl/min, 
with physiological saline (PS), continuously gassed with 
5% COz in 02, containing (mM): NaC1, 140; KHCO3, 
5; MgCI2, 1 ; CaCI2, 2.2; glucose, 10; TRIS-HEPES, 10; 
pH 7.1-7.2 and 0.01% BSA. Fractions were collected 
every 4 min and stored at - 7 0 ~  before subsequent 
radioimmunoassay of secreted AVP and OT (for details 
see Cazalis et al. 1985). Secretion was evoked with either 
electrical stimulation or with depolarizing concentrations 
of potassium (60 or 100 mM). Osmotic equivalence was 
maintained in solutions containing elevated K + by de- 
creasing the Na + concentration accordingly. In some 
experiments, Na+-free media was used as it induces a 
much larger K +-evoked hormone release (Dreifuss et al. 
1971; Nordmann 1976) and thus was important for 
studying small differences in neuropeptide release in the 
presence or absence of opioid molecules. In those experi- 
ments, the release was evoked with Na+-free saline con- 
taining 100 mM K + and the osmolarity adjusted with 
choline. In the case of electrically induced depolarization, 
the neural lobes were stimulated with electrical pulses 
arranged in 4 bursts, separated by 21-s silent intervals, 
which had a pattern of discharge similar to the bursting 
activity of vasopressin cells in vivo (for details see Cazalis 
et al. 1985). Each burst contained 348 pulses given at a 
mean frequency of 13 Hz. This was used instead of con- 
stant frequency stimulation, as it is a more appropriate 
stimulation paradigm. We have stressed elsewhere the 
importance of the use of bursts of pulses in studies on the 
release of AVP from isolated neural lobes (Cazalis et al. 
1985). For K +-stimulation, neural lobes or isolated nerve 
endings were depolarized during a period of 8 or 10 min. 
Isolated nerve endings were prepared as described 
previously (Cazalis et al. 1987a). Following isolation, the 
nerve endings were resuspended in PS (see above) and 
loaded onto 0.22 gm filters (GS, Millipore). The filters 
were perfused for 45 min at a flow rate of 25 gl/min 
which was then increased to 50 gl/min. Collection of the 
perfusate started 90 rain after loading the endings on the 
filter. Collected fractions were of 4 min duration. 
In most of the experiments reported in this paper, we 
used the $2/S~ paradigm for analysis of secretion de- 
scribed by Iversen et al. (1980). The neural lobes, or the 
nerve endings, received two stimulation periods (St and 
$2) separated by a period of 60 min. The amount of 
hormone release during each stimulation period was cal- 
culated by subtracting the amount of hormone released 
under basal conditions from that observed during, and 
directly after the stimulus. The effects of opioid agonists 
or antagonists were tested by adding them 20 min prior 
to and during the second stimulation period ($2). The 
effect of different molecules tested was then expressed by 
the changes in the ratio Sz/St from controls in which no 
agonists nor antagonists were added. 
[Ca2+]i measurements in isolated terminals 
Determination of [Ca 2 +]i in individual nerve endings was 
performed by dual wavelength microspectrofluorimetry 
following loading with fura-2/AM. The microspectro- 
fluorimetry equipment and perfusion chamber utilized to 
monitor [Ca2+]i in individual or small groups of nerve 
endings was identical to that previously described (Stuen- 
kel 1990). All measurements were performed at 37 ~ C in 
a chamber providing rapid exchange of the superfusing 
physiological saline. The fluorescence ratio was con- 
verted to [Ca 2 +]i using the equation of Grynkiewicz et al. 
(1985). Values of Rmin, Rma x and Fo/Fs were determined 
using an external standard calibration technique. A Kd 
value for fura-2 of 224 nM was taken from the literature. 
Because, according to some authors, AVP-containing 
nerve endings respond differently to opioids than OT- 
containing terminals, we analyzed the effects of drugs on 
groups of 3-6 nerve endings to avoid misleading results, 
which could have been obtained from a single nerve- 
ending class. 
Chemicals 
Naloxone and U-50 488 were a gift from John Bicknell 
(Babraham, England). Ethylketocyclazocine, etorphin 
and diprenorphin were kindly given to us by Pierre Gi- 
raud (Marseille, France). We are grateful to Dr. Kempf 
(Strasbourg, France) for giving us MR 2266, which was 
a gift from Boehringer. Dynorphin A(1- t3) or dynorphin 
Act- s) was obtained from CRB, Cambridge (England) or 
Peninsula Laboratories (USA); in some experiments it 
was diluted in saline containing protease inhibitors at the 
following concentrations : aprotinin, 0.1 mg ml- t ; pep- 
statin A 10-3M; Leupeptin 10-aM; TAME 
0.1 mg ml -t  ; chloroquine 10 .4 M; soybean trypsin in- 
hibitor 10 -2 M and PMSF 10 -3 M. 
Results 
Effects of opioid agonists on neurohormone release 
The effects of dynorphin Act_ 13) and U-50 488, opioid 
kappa-receptor agonists, on electrically evoked release of 
AVP and OT from intact neural lobes are presented in 
Figure 1. No significant change in the release of AVP was 
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Fig. la, 5. Effects of kappa-receptor agonists on 
electrically evoked hormone release from isolated 
neural lobes. Each neural lobe received two periods 
($1 and Sz) of stimulation (4 bursts, see Materials 
and methods), a AVP release; 5 oxytocin release. 
C, Control; Dyn, dynorphin A a _ 13) (10-6 M); 
Eto, etorphin 10 -5 M; Eth, ethylketocyclazocide 
10 .5 M; Nal, naloxone 10 -s  M. Data are 
means :t: SEM and the number of experiments are 
given in parantheses above the columns. The sig- 
nificance level is relative to controls (Mann-Whit- 
ney U test) with *: P<0.03;  **: P<0.003;  
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Fig. 2a-d. Representative recordings 
showing the effect of opioid agonists 
on basal [CaZ+]i and K+-evoked in- 
crease in [Ca2+]i . Records show the ef- 
fect of a dynorphin A(1-13) (10 -6 M), 
b dynorphin A(1-8) ( 10-6 M), c 
U50488 (U50, 10 -6 M) and d etorphin 
(Etor, 10 .5 M). Agonists were added 
prior and during a K § 
(25 mM, a, e, d; 50 mM, b) depolariza- 
tion. Signal represents that recorded 
from groups of 3 6 isolated nerve ter- 
minals. Switching of solutions as in- 
dicated above traces 
or dynorphin A(1-s> at 10 -6  M, when compared to con- 
trol stimulation periods. The values for $2/$1 were 
0.80 + 0.10 (n --- 6) for dynorphin A(~ _ ~ 3) and 0.99 • 0.09 
(n = 5) for dynorphin A<1-8), respectively. In contrast, a 
24% inhibition of OT secretion to dynorphin A(~-~3) 
(S2/S~ = 0.76 + 0.06, n = 9) treatment was observed (Fig. 
lb). Similarly, a slight, but significant decrease of OT 
release was observed with dynorphin A(~-8) ($2/ 
$1 = 0.804-0.04, n= 5). To examine if the lack of effect 
of the dynorphin on AVP secretion may have resulted 
from proteolytic degradation, similar experiments were 
performed in the presence of protease inhibitors. The 
results were however, not significantly different from 
those obtained in the absence of the inhibitors and, 
therefore, the results in the presence and absence of 
inhibitors have been pooled. Note that the amplitude of 
the secretory response were not significantly different in 
preparations in the presence or the absence of the in- 
hibitors. 
Selectivity of the dynorphin effect for the kappa- 
receptor type was investigated by using two other opioid 
receptor agonists, etorphin and ethylketocyclazocine, 
which show less selectivity for this receptor type. Of 
importance, a significant reduction in the electrically 
evoked release of both AVP and OT at 10 -5 M from 
intact neural lobes (Fig. la, b) was observed. Lower 
concentrations, however, were without effect. Naloxone 
(10-5 M), a non-selective opiate receptor antagonist, was 
effective in antagonizing the inhibitory effects of etorphin 
(10 -5 M) on the electrically induced secretion of both 
AVP and OT (Fig. 1). Naloxone alone was without effect 
on evoked AVP secretion (Fig. la), but potentiated elec- 
trically induced OT secretion (Fig. l b). Furthermore, 
etorphin had no effect on the K § release of AVP 
release and OT from the isolated perfused nerve endings 
(not shown). 
Additional experiments examined, in preparations of 
isolated nerve endings, the effects of dynorphin and a 
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Fig. 3a--d. Averaged results comparing the effect of opioid agonists 
on the K+-evoked increase in [Ca2+]i . Two control stimulations 
(25 mM K § 45 s) preceded each test stimulation in the presence of 
a dynorphin A(1_ 13) (DYN, 10-6 M), b dynorphin A(x- 8) (DYN, 
10 -6 M), c etorphin (ETO, 10 -5 M) and d U50 488 (U50, 10 -6 M). 
The results represent the mean+ SEM determined from at least 
three separate determinations. The significance level is relative to 
controls (Mann-Whitney U test) with *: P < 0.04 
stable opioid kappa-receptor agonist, U-50 488, on AVP 
and OT release. Secretion was evoked by depolarization 
of the nerve endings with saline containing 60 mM 
potassium for a period of 10 min. The ratios $2/$1 for the 
release of AVP and OT were for controls 0.594-0.07 
(n = 9) and 0.77 + 0.05 (n = 20), respectively (means + 
SEM). In the experiments in which U-50 488 (10 .5 M) 
was added during the second depolarization period, the 
values obtained were 0.59 + 0.07 (n = 11) and 0.68 + 0.07 
(n = 11), respectively, and were not significantly different 
from the controls. Using the $2/$1 paradigm we found 
that the secretory response to 25 mM K § was not modi- 
fied, in contrast to the Ca 2+ response, by U-50488 
(10 -6 M) [Control, 0.93+0.04 (n---5); U-50 488, 
0.94 4-0.04 (n = 6)]. Likewise, dynorphin was also found 
to have no effect on the release of AVP and OT from the 
isolated perfused nerve endings. Thus, not all the "selec- 
tive" kappa-receptor agonists are equally effective in 
modulating the evoked release of AVP and OT. 
Effects of opioid agonists on [Ca2+]i 
The effects of several opioid receptor agonists on resting 
and K+-evoked (25 raM) [Ca2+]i was investigated in iso- 
lated nerve endings loaded with the CaZ+-sensitive, 
fluorescent probe fura-2. Figure 2 shows that dynorphin 
A . _  13) and dynorphin A(~_8) at 10 -6 M had no signifi- 
cant effect on either basal [Ca2+]i or the K+-evoked 
increase in [Ca2+]i. In comparison, U-50 488 (10 -6 M) 
produced a small, but significant, decrease in the K +- 
induced increase in [Ca 2 +]i while basal [Ca2+]i was not 
affected by this agonist. In each case, recovery was com- 
plete after washout of the drug, as judged by the response 
obtained during a fourth stimulation. The data are sum- 
marized in Fig. 3. Statistical analysis showed that among 
the agonists used, only U-50488 had a significant 
(P < 0.01) inhibitory effect on the increased calcium con- 
centration triggered by an elevation of the external 
potassium concentration. 
Effects of opioid antagonists on A VP and OT release 
To address further the specificity of opioid actions, the 
effect of opioid antagonists on AVP and OT release were 
investigated in neural lobes stimulated electrically using 
the $2/$1 paradigm (see above). Diprenorphin (10 -5 M) 
or MR 2266 (10 -6  M) ,  which are considered as selective 
antagonists (but see Smith et al. 1984) for kappa-recep- 
tors, decreased by a small (26 and 25%) but significant 
extent the electrically evoked release of AVP and OT 
(Fig. 4a). However, potassium-induced hormone se- 
cretion from the neurohypophysis was not changed sig- 
nificantly by MR 2266 (Fig. 4b). In all cases, no signifi- 
cant effects of the antagonists were found on basal se- 
cretion of either AVP or OT (not illustrated). 
Effects of opioid antagonists on [Ca2+]i 
Potential effects of opioid antagonists on [Ca2+]i were 
























Fig. 4a, b. Effects of kappa-receptor antagonists on 
evoked hormone release from: a electrically stimu- 
lated (4 bursts, see Materials and methods) neural 
lobes and b 60 mM K+-depolarized isolated nerve 
endings. C, Control; Dip, diprenorphin 10-5 M; 
MR 2266 10 -6 M. Results are expressed as $I/$2 
ratios. Data are given as means 4-SEM, with the 
number of experiments being above the columns. 
The significance level is relative to controls (Mann- 
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Fig. ha, b. Representative recordings showing the effect of opioid 
antagonists on basal [Ca2+]j and K+-evoked increase in [Ca2+]i. 
Records show effect ofa naloxone (NAL, 10 -5 M) and b MR 2266 
(MR, 10 .6 M) added prior to and during a K+-induced (25 mM) 
depolarization. Signal recorded from groups of 3-6 nerve endings. 
Switching of solutions as indicated 
100 1 0 0  
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Fig. 6a, b. Averaged results comparing the effect of opioid antago- 
nists on the K+-evoked increase in [Ca2+]i. Two control stimula- 
tions (25mM K +, 45 s) preceded each test stimulation in the 
presence of a MR 2266 (MR, 10 -6 M) and b naloxone (NAL, 
10 -5 M). The results represent the mean• SEM determined from 
at least three separate determinations 
potassium. Both naloxone (10 5 M) and M R  2266 
(10 -6 M) were without  significant effect on either basal 
[Ca2+]i or the stimulated increase in [Ca2+]~ (Fig. 5). 
Figure 6 summarizes the data obtained with the different 
antagonists and demonstrates  the lack of  effects. Fur-  
thermore,  in two other experiments diprenorphin also 
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Table 1. Effects of naloxone on the K +-induced release of AVP and 
OT from nerve endings isolated from control and dehydrated rats. 
Results are expressed as $2/S 1 ratios, as described in the Materials 
and methods section. Rats were dehydrated for a period of 3 days. 
The nerve endings were depolarized with 60 mM potassium for a 
10 min period. Data are means• SEM and the number of experi- 
ments are given in parentheses 
VP Sz/S I OT $2/S 1 
Normal rats 
Control 0.884-0.09 (12)  0.91• (7)  
Naloxone 10 -5 M 0.74• (14)  0.97:k0.10 (14) 
Dehydrated rats 
Control 0.86• (12)  0.91• (24) 
Naloxone 10 -s M 0.80• (14)  0.97• (12) 
failed to modify  the calcium response to the K +-induced 
depolarization. Thus, none of the opioid antagonists 
used in this study had an effect on [Ca z +]~ associated with 
depolarization of  the nerve terminals. 
Effects o f  physiological state on responsiveness to 
opioids 
The effect of  opiate receptor antagonists on hormone  
release f rom neural lobes obtained f rom dehydrated rats 
was studied. Under  these conditions, the electrical activ- 
ity of  the magnocellular neurons is greatly enhanced (for 
review see Poulain and Wakerley 1982), leading to in- 
creased secretion. The rats were dehydrated for 3 days, 
and the isolated neurohypophyses  were stimulated with 
60 m M  potassium using the $2/$1 paradigm. The mean 
control values for AVP and OT release were, respective- 
ly, 0 .94+0.14 (n=10)  and 0 .91+0.04 (n=24) .  In the 
presence of  the opiate receptor antagonist  M R  2266 
(10 -6 M), the mean values were 1.02• 0.15 (n=  18) and 
0 .94•  (n=  14) for AVP and OT, respectively. In 
comparison,  naloxone (10 .5 M), was without effect on 
both AVP and OT secretion triggered by depolarization 
with elevated K + (Table 1). 
Discuss ion 
The presence of  opiate receptors in the neural lobe was 
first described more than a decade ago (Simantov and 
Snyder 1977), but their nature and precise localization 
within the tissue have been difficult to analyze as judged 
by the contradictory results obtained f rom different lab- 
oratories. Opiate receptors were initially believed to be 
localized on the pituicytes (Lightman et al. 1983; Bunn 
et al. 1985), but later reports described their presence also 
on neurosecretory nerve terminals (Herkenham et al. 
1986; Pesce et al. 1987; Falke and Mart in  1988). Quan- 
titative autoradiography of  tritiated ligand-binding 
showed that  the g- and 6-like receptors were virtually 
absent in the neural lobe and that  only the presence of  
kappa-opioid  receptors could be demonstrated (Bunn et 
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al. 1985; Herkenham et al. 1986; Castanas et al. 1986; 
Gersterberger and Barden 1986; Falke and Martin 
1988). Recently, this analysis has been extended with 
similar findings to preparations of isolated neurohy- 
pophysial nerve terminals (Pesce et al. 1987; Falke and 
Martin 1988). Yet [H3]ethylketocyclazocine has been 
shown to exhibit high-affinity binding with complex 
isotherms consistent with the presence of multiple classes 
of binding sites (Gertsberger and Barden 1986; Pesce et 
al. 1987). In addition, U-50 488 or dynorphin A, -s ) ,  a 
naturally occurring kappa-ligand, only slowly and incom- 
pletely displaces the radiolabeled antagonist diprenor- 
phin (Gertsberger and Barden 1986; Falke and Martin 
1988). Finally, in a very careful analysis of the distribu- 
tion of receptors in the neural lobe, Falke and Martin 
(1988) found the opioid binding sites were preferentially 
localized on neurosecretory terminals containing oxyto- 
cin. Thus taken together autoradiographic and binding 
studies suggest that on the neurohypophysial nerve end- 
ings kappa-receptors represent the largest population of 
opioid receptors, but the presence of g- or g-type recep- 
tors cannot be entirely excluded. 
Both the localization of endogenous dynorphin in the 
nerve endings and opiate receptors in the neural lobe 
would suggest that the opioids could play a role in the 
control of the release of neurohypophysial hormones. 
However, the results obtained by different groups are far 
from convincing. Interesting examples are the effects of 
the Leu-enkephalin analogue DADLE and of ~-endor- 
phin on the release of hormone from the neural lobe. It 
was first demonstrated that both molecules have an in- 
hibitory effect on the electrically evoked AVP release 
(Iversen et al. 1980; Lightman et al. 1982) and that an 
enkephalin analogue decreased the secretion of oxytocin. 
However, others have been unable to find a significant 
effect of these molecules on hormone release (Bicknell 
and Leng 1982; Denker et al. 1982; Lutz-Bucher et al. 
1982; Pitzel and Konig 1984; Nordmann et al. 1986). 
Similarly, contradictory data have been obtained with 
other opioid molecules (for references, see Table 2 in 
Nordmann et al. 1986). 
The present study attempted to explain the different 
and contradictory results obtained by different groups on 
the modulation of neurohypophysial hormone release by 
opioid molecules. In a recent study (Zhao et al. 1988a), 
it had been shown that K+-induced secretion of both 
AVP and OT from isolated neurohypophysial nerve ter- 
minals was inhibited by two specific kappa-agonists, 
namely, U-50 488 and dynorphin A(1-13) (for specificity 
see Gairin et al. 1985; Von Voigtlander et al. 1983). This 
effect was prevented by the non-specific antagonist nal- 
oxone (Zhao et al. 1988a). Similarly, U-50488 was 
shown to inhibit, by about 30%, the electrically induced 
AVP and OT release, and this effect was prevented by a 
tenfold molar excess of naloxone (Zhao et al. 1988b). 
However, DAGO, which is believed to be specific for the 
g-type receptor, also affected, although to a smaller ex- 
tent, the release of AVP and possibly that of OT. It has 
to be pointed out that earlier reports failed to observe an 
inhibitory effect of kappa-agonists on secretion (Bicknell 
et al. 1985). The results of the present study failed to 
demonstrate an effect of U-50 488 on the K+-evoked 
AVP and OT release from isolated nerve endings, al- 
though a decrease in evoked [Ca2+]i occurred. On the 
other hand, dynorphin A(1-13), another kappa receptor 
agonist, inhibited the electrically-induced release of OT 
but was without effect on AVP secretion (Fig. 1) or on 
K+-evoked changes in [Ca2+]i in isolated nerve endings 
(Figs. 2, 3). It should be pointed out that effects of 
opiates on electrically induced release on OT (but not 
AVP) were only observed when the neural lobes were 
stimulated at low frequency (4 Hz) (Bondy et al. 1988). 
However, as the magnocellular neurons do not generally 
fire at such frequencies (see for details Poulain and 
Wakerley, 1982) these results might have no relevance for 
studies in vivo. The very significant inhibitory effects of 
etorphin and ethylketocylazocin on secretion (Fig. 1) are 
of interest because these molecules show less specificity 
among the opioid receptors (Wood 1984). However, ac- 
count should be taken of the relatively high concentra- 
tions used in these experiments when interpreting the 
physiological role of opiates in the stimulus-secretion 
mechanism, at the level of the neurohypophysial nerve 
endings. It suggests the results presented here, and in 
other studies, for the opiate effects in this tissue should 
be assessed with caution. 
The lack of effect of the two antagonists, diprenorphin 
and MR 2266, on AVP and OT release and on evoked 
changes in [Ca 2 +]i is in contrast to the results of Bicknell 
et al. (1985), who observed potentiation of OT and AVP 
release by MR 2266. Our results are, however, in agree- 
ment with the observation made by the same authors 
that, at high concentrations, the antagonists show a 
strong agonist-like effect. Finally our results confirm that 
at high doses (10- 5 M) naloxone - which, at lower doses, 
had no effect on the secretory mechanism in normal rats 
(Nordmann et al. 1986) - potentiates the electrically 
induced OT release and can overcome the inhibitory 
effect of agonists such as etorphin. Naloxone had no 
effect, however, on perfused isolated nerve endings stim- 
ulated with potassium. This is in agreement with the 
results of Zhao et al. (1988a) who found that the release 
of OT from isolated nerve terminals was not affected by 
naloxone. 
Although the present data brings into doubt the speci- 
ficity or identity of the receptors with which opiates could 
act on the secretion of AVP and OT, it clearly demon- 
strates that the calcium increase in the cytoplasm, which 
follows the depolarization of the isolated nerve termi- 
nals, is not systematically affected by the opioid agonists. 
It has been known for some time that activation of kappa 
receptors can reduce the calcium current in neurons 
(North and Williams 1985; MacDonald and Wertz 1986; 
North 1986), and this should diminish the evoked trans- 
mitter release. However, the present data show that the 
spatially averaged calcium increase in the depolarized 
isolated neurohypophysial nerve endings is not affected 
by dynorphin A(1-13) or dynorphin A(1-8) acting on 
opiate receptors. The inhibitory effect of U-50 488 on the 
potassium-induced calcium increase corresponds to a 
small change of [Ca2+]i (ca. 65 nM). Thus, if opioid 
molecules can modulate the secretion of AVP and OT, 
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they  m a y  act  a t  a s tep d o w n s t r e a m  f rom the ac t i va t i on  
o f  the  ca lc ium channels .  As  op i a t e  molecules  do  no t  act  
on  pe rmeab i l i z ed  nerve endings  (unpub l i shed  obse rva -  
t ions) ,  i.e. nerve  endings  in which  the d e p o l a r i z a t i o n  step 
is b y p a s s e d  (Cazal is  et al. 1987b), the  r e m a i n i n g  s tep at  
which  op i a t e  molecu les  cou ld  act  w o u l d  be at  or  c lose to 
the  ex te rna l  site o f  the  p l a s m a  m e m b r a n e  at  which  exocy-  
tosis  occurs .  
M o s t  o f  the exper imen t s  descr ibed  in this  p a p e r  have  
been  p e r f o r m e d  us ing  p a r a d i g m s  s imi lar  to those  used  by  
o the r  researchers  bu t  who  o b t a i n e d  resul ts  different  f rom 
ours.  One  poss ib i l i ty  cou ld  be tha t  an imals ,  even or igi-  
na l ly  f rom the same s t ra in ,  can  differ c o n s i d e r a b l y  in the  
way  they  r e s p o n d  to o p i o i d  molecules .  A n o t h e r  a l ter -  
na t ive  w o u l d  be to cons ide r  the  phys io log ica l  s ta te  o f  the  
an imal .  I t  is ou r  con t en t ion  tha t  the  m o d u l a t i o n  o f  neu- 
r o h y p o p h y s i a l  h o r m o n e  secre t ion  by  o p i o i d  molecu les  
r emains  un reso lved  and  awai t s  the  d e v e l o p m e n t  o f  h ighly  
specific o p i o i d  agonis t s  a n d  an t agon i s t s  a n d  the precise  
c h a r a c t e r i z a t i o n  o f  the  op io id  recep to rs  involved.  
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